Please wait...


Generic Name: binimetinib (BIN i ME ti nib)
Brand Names: Mektovi
Mektovi (binimetinib) + Braftovi (encorafenib) combination is used to treat melanoma with a BRAFV600E or BRAFV600K mutation. Includes Mektovi (binimetinib) side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Mektovi

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Mektovi (binimetinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Mektovi is a prescription medicine used in combination with another medicine called encorafenib (Braftovi) to treat melanoma (skin cancer) in people who have a "BRAF" gene mutation. These medicines are for use in treating melanoma that cannot be treated with surgery or has spread to other parts of the body. Mektovi may also be used for purposes not listed in this medication guide. Mektovi can cause birth defects. Do not use if you are pregnant. Avoid getting pregnant while using Mektovi and for at least 30 days after your last dose. Learn more

Mektovi Side Effects

Mektovi Side Effects

Note: This document contains side effect information about binimetinib. Some of the dosage forms listed on this page may not apply to the brand name Mektovi.

For the Consumer

Applies to binimetinib: oral tablet

Along with its needed effects, binimetinib (the active ingredient contained in Mektovi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking binimetinib:

More common

  • Bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blurred vision or any other change in vision
  • chest pain
  • coughing up blood
  • decreased urine output
  • difficulty in breathing or swallowing
  • dilated neck veins
  • dizziness
  • extreme tiredness or weakness
  • fever
  • headache
  • hoarseness
  • increased menstrual flow or vaginal bleeding
  • irregular breathing
  • irregular heartbeat
  • irritation
  • itching, hives, skin rash
  • joint pain, stiffness, or swelling
  • nervousness
  • nosebleed
  • paralysis
  • pounding in the ears
  • prolonged bleeding from cuts
  • rapid weight gain
  • red or black, tarry stools
  • red or dark brown urine
  • redness of the skin
  • slow or fast heartbeat
  • stomach cramps
  • tenderness
  • tightness in the chest
  • tingling of the hands or feet
  • trouble seeing
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • watery or bloody diarrhea

Some side effects of binimetinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Constipation
  • diarrhea
  • nausea
  • stomach pain
  • vomiting

For Healthcare Professionals

Applies to binimetinib: oral tablet


Very common (10% or more): Anemia (36%), hemorrhage (19%), leukopenia (13%), lymphoma (13%), neutropenia (13%)

Common (1% to 10%): Venous thromboembolism (VTE)


Common (1% to 10%): Hypersensitivity


Uncommon (0.1% to 1%): Rhabdomyolysis


Very common (10% or more): Retinopathy (20%), visual impairment (20%)

Common (1% to 10%): Retinal detachment, macular edema, uveitis

Uncommon (0.1% to 1%): Retinal vein occlusion


Very common (10% or more): Hyponatremia (18%), peripheral edema (13%)


Very common (10% or more): Increased gamma glutamyl transferase (45%)

Common (1% to 10%): Alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased

Uncommon (0.1% to 1%): Alkaline phosphatase increased


Uncommon (0.1% to 1%): Interstitial lung disease


Very common (10% or more): Fatigue (43%), pyrexia (18%)

Nervous system

Very common (10% or more): Dizziness (15%)


Very common (10% or more): Increased creatinine (93%), increased creatine phosphokinase (58%)


Very common (10% or more): Hypertension (11%)

Common (1% to 10%): Cardiomyopathy, fatal intracranial hemorrhage (in the setting of new or progressive brain metastases)


Very common (10% or more): Rash (22%)

Common (1% to 10%): Panniculitis


Very common (10% or more): Nausea (41%), diarrhea (36%), vomiting (30%), abdominal pain (28%), constipation (22%)

Common (1% to 10%): Rectal hemorrhage, hematochezia, hemorrhoidal hemorrhage, colitis

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Mektovi